Galena Biopharma (GALE) Receiving Somewhat Favorable News Coverage, Report Finds
Media stories about Galena Biopharma (NASDAQ:GALE) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Galena Biopharma earned a daily sentiment score of 0.00 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 88 out of 100, meaning that recent news coverage is very likely to have an effect on the company’s share price in the next few days.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- -$0.15 Earnings Per Share Expected for Galena Biopharma, Inc. (GALE) This Quarter (americanbankingnews.com)
- Keloid Treatment Market Research Report 2016: Industry Outlook, Growth, Trends and Forecast (sbwire.com)
- Galena Biopharma, Inc. (GALE) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Calling all Bargain Hunters: Stock Update on Galena Biopharma, Inc. (NASDAQ:GALE) – FLBC News (flbcnews.com)
- Keloid Treatment Market Professional Survey Report 2024 (openpr.com)
Galena Biopharma (NASDAQ GALE) traded up 0.736% during mid-day trading on Wednesday, hitting $0.561. 169,949 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $0.57 and its 200-day moving average price is $1.05. The stock’s market cap is $21.00 million. Galena Biopharma has a one year low of $0.52 and a one year high of $49.80.
Galena Biopharma (NASDAQ:GALE) last posted its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.13. During the same period in the previous year, the firm posted ($0.07) EPS. On average, analysts forecast that Galena Biopharma will post ($0.56) EPS for the current fiscal year.
A number of research analysts have weighed in on GALE shares. Zacks Investment Research upgraded shares of Galena Biopharma from a “hold” rating to a “strong-buy” rating and set a $0.75 price objective on the stock in a research report on Monday, March 20th. ValuEngine cut shares of Galena Biopharma from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $2.27.
About Galena Biopharma
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Stock Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related stocks with our FREE daily email newsletter.